Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products
- PMID: 28004346
- DOI: 10.1208/s12248-016-0025-9
Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products
Abstract
Oral modified-release (MR) products are dosage forms administered through the mouth and designed to release drug in a controlled manner to achieve maximum efficacy, minimal side effects, and better patient compliance. With significant progress in pharmaceutical technologies and favored therapeutic benefit, more and more oral MR products including the generic versions of these products are being developed, marketed, and used in the USA. Because different types of MR products may exhibit unique drug release modes and specific pharmacokinetic profiles, a better understanding of the regulation and evaluation of these generic MR products can help development and marketing of generic MR products that are therapeutically equivalent to the corresponding reference product. This review summarizes the general regulatory requirements for establishing bioequivalence between generic and reference oral MR products. In addition, some special regulatory considerations for bioequivalence evaluation are highlighted with examples of specific oral MR drug products.
Keywords: bioavailability; bioequivalence; modified release; oral dosage form.
Similar articles
-
Modeling and simulation of biopharmaceutical performance.Clin Pharmacol Ther. 2014 May;95(5):480-2. doi: 10.1038/clpt.2014.40. Clin Pharmacol Ther. 2014. PMID: 24747237
-
Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended-Release Products.J Clin Pharmacol. 2019 Sep;59(9):1252-1263. doi: 10.1002/jcph.1017. Epub 2019 May 14. J Clin Pharmacol. 2019. PMID: 31087553
-
Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan.J Pharm Sci. 2016 Aug;105(8):2270-7. doi: 10.1016/j.xphs.2016.05.026. Epub 2016 Jun 30. J Pharm Sci. 2016. PMID: 27372551
-
Selection of oral controlled-release drugs: a critical decision for the physician.South Med J. 1993 Feb;86(2):208-14. doi: 10.1097/00007611-199302000-00013. South Med J. 1993. PMID: 8434294 Review.
-
Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products.AAPS J. 2016 Jul;18(4):1032-8. doi: 10.1208/s12248-016-9932-z. Epub 2016 May 16. AAPS J. 2016. PMID: 27184578 Review.
Cited by
-
Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of Gegen Qinlian Decoction for Rotavirus Enteritis.Evid Based Complement Alternat Med. 2020 Jul 29;2020:2957567. doi: 10.1155/2020/2957567. eCollection 2020. Evid Based Complement Alternat Med. 2020. PMID: 32802121 Free PMC article.
-
Industry Perspective on Standardizing Food-Effect Studies for New Drug Development.Clin Pharmacokinet. 2018 Aug;57(8):901-909. doi: 10.1007/s40262-018-0630-0. Clin Pharmacokinet. 2018. PMID: 29460023 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical